Category : EVENTS | Date : Fév 11, 2023

Early 2023, the 300th patient was included in the INTENSE-TBM trial.

The year 2022 has been marked by entering in a routine phase of the trial, with 10 sites opened and recruiting and no major issue detected in terms of implementation, medical follow-up nor safety.

This included constant efforts in all the countries to boost the inclusions by better communicating and improving inclusion process. This included also at the consortium level, the identification of the obstacles that could have been overcome by amending the protocol without impacting on the safety of the patients.